HDAC9 and neoplasm: Epigenetic modifiers such as HDAC inhibitors have thus been identified to promote sensitization of tumor cells to PD-1/PD-L1 immune checkpoint inhibitors via reversal of MDSC’s immunosuppressive effect on the cancer milieu, demonstrating synergistic effects with immunotherapeutic options in solid tumors (212).